Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)

ConclusionThere are no differences between mirabegron and antimuscarinics in terms of patient-reported OAB symptom bother and HRQoL.Trial RegistrationClinicalTrials.gov identifier, NCT02386072.FundingAstellas Pharma Global Development, Inc.Plain Language SummaryPlain language summary available for this article.

http://link.springer.com/10.1007/s12325-019-00994-7

Source: Advances in Therapy - June 19, 2019 Category: Drugs & Pharmacology Source Type: research